Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Shareholder Meeting (September 2026)
11 slides from Onesource Specialty Pharma's shareholder meeting presentation, Sep 23, 2026
Slide 1: 19th Annual General Meeting (AGM)
19th Annual General Meeting (AGM) September 23rd, 2026 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 3: A majority independent board provides oversight backed by deep global pharma and governance expertise
A majority independent board provides oversight backed by deep global pharma and governance expertise Arun Kumar Debarati Sen Dr. Claudio Albrecht Colin Bond Chairperson and Non-Executive, Non-Executive, Non-Executive, Non-Executive Director Independent Director Independent Director Independent Dire
Slide 4: Building a specialty CDMO platform with offerings across complex modalities
Building a specialty CDMO platform with offerings across complex modalities ONE-OF-A-KIND INTEGRATED INDUSTRY-LEADING ROBUST DEMAND ACROSS A BUILT ON TALENT CDMO PLATFORM MANUFACTURING CAPACITIES DIVERSIFIED CUSTOMER BASE AND TRUST Leading 5 70+ 1,700+ Multi-Modality CDMO State-of-the-Art Active RFP
Slide 5: Expanded customer partnerships, advanced capacity expansion, and building our biologics footprint
Expanded customer partnerships, advanced capacity expansion, and building our biologics footprint 30+ Launches 10+ New Logos $100M Capex Last 15 Months 7+ Markets Served 80+ Customers Phase 1 Completed Leadership in DDC Building Biologics Business Deepening Base Businesses 4 20+ 5 4x 2x 5B caps G7 S
Slide 6: Building a quality-first organisation
Building a quality-first organisation Quality is our responsibility and our promise. We design it into every process, deliver it in every product, and Our Quality Policy uphold it through our systems – always meeting global standards and exceeding customer expectations. Enablers Architecture Quality
Slide 7: FY26 a transition year; expanding capability and capacity to deliver FY27 and beyond
FY26 a transition year; expanding capability and capacity to deliver FY27 and beyond In $ m FY26 FY25 YoY Financial Snapshot Revenue 158.1 160.7 (2%) • Full-year revenue declined marginally by 2% EBITDA 33.8 51.9 (35%) YoY, reflecting a softer second half impacted by EBITDA margin (%) 21% 32% (1089b
Slide 8: Q1FY27: Performance driven by semaglutide ramp-up delivering 39% YoY EBITDA growth
Q1FY27: Performance driven by semaglutide ramp-up delivering 39% YoY EBITDA growth In $ m Q1FY27 QoQ Q1FY26 YoY Financial Snapshot Revenue 47.5 +5% 34.6 +37% • Revenue of $47.5m/₹4,490m EBITDA 13.1 +34% 9.4 +39% ↑5% QoQ and ↑37% YoY EBITDA margin (%) 27.5% +600bps 27.0% +43bps driven by growth in se
Slide 9: Building for sustainable value creation
Building for sustainable value creation Environmental Social Governance ✓ 81% renewable energy ✓ Zero work-related injuries; ✓ 98% average board meeting contribution zero fatalities attendance ✓ 100% Zero Liquid Discharge ✓ ₹22 million spent on CSR ✓ 5/8 independent directors across our manufacturin
Slide 10: Agenda for AGM FY26
Agenda for AGM FY26 Item 1: To consider and adopt the audited financial statements (including consolidated financial statements) of the Company for the financial year ended March 31, 2026, and the reports of the Board of Directors and Auditors thereon Ordinary Business Item 2: Re-appointment of Neer
Slide 11: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I
OneSource Specialty Pharma — Shareholder Meeting (September 2026) on 6ix